Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
The investment will accelerate the overall Sarclisa development program
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
he financing was significantly oversubscribed with high demand from both existing and new investors.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Subscribe To Our Newsletter & Stay Updated
